Many studies indicate that low S-phase and diploid DNA content are associated with a relatively good prognosis. No membranous staining identified. This test is FDA approved for formalin-fixed tissue only. Its performance characteristics have been determined by ARUP Laboratories. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas.
Mitotic count is the single best indicator.
Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Hedley DW, et al. Consensus review of the clinical utility of DNA cytometry of the breast. MacGrogan G, et al.